{"id":"degludec-sc","safety":{"commonSideEffects":["hypoglycemia","injection site reactions","weight gain"],"contraindications":["hypersensitivity to insulin degludec or excipients","episodes of hypoglycemia"]},"_chembl":{"chemblId":"CHEMBL2107869","moleculeType":"Protein"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Insulin receptor","explanation":"Degludec is an insulin analog that binds to insulin receptors on cells, promoting glucose uptake from the bloodstream into tissues. Its molecular structure allows for formation of multi-hexamers after subcutaneous injection, creating a depot that provides slow, steady insulin release over an extended period.","oneSentence":"Binds to insulin receptors to facilitate glucose uptake and regulate blood sugar levels with ultra-long duration of action."},"_scrapedAt":"2026-03-28T05:01:35.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123390,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"insulin glargine","brand":"Lantus","company":"Sanofi","rationale":"Long-acting basal insulin for once-daily diabetes management"},{"name":"insulin detemir","brand":"Levemir","company":"Novo Nordisk","rationale":"Long-acting basal insulin analog for diabetes control"},{"name":"insulin glargine U300","brand":"Toujeo","company":"Sanofi","rationale":"Ultra-long-acting concentrated basal insulin formulation"}],"description":"Degludec SC is an ultra-long-acting basal insulin analog in Phase 1 development by Eli Lilly and Company. It is designed to provide extended glucose control with once-daily dosing for diabetes management. The subcutaneous formulation aims to offer stable insulin coverage over extended periods.","indications":{"approved":[{"status":"investigational","condition":"Type 1 diabetes mellitus","patientPopulation":"Adult and paediatric patients requiring basal insulin"},{"status":"investigational","condition":"Type 2 diabetes mellitus","patientPopulation":"Adult patients requiring basal insulin therapy"}]},"trialDetails":[{"nctId":"NCT06945406","phase":"PHASE1","title":"A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-16","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT07215312","phase":"PHASE2","title":"A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-13","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT06280703","phase":"PHASE1","title":"A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-15","conditions":"Healthy, Type 1 Diabetes Mellitus","enrollment":118},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05463744","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-12","conditions":"Type 1 Diabetes, Diabetes","enrollment":692},{"nctId":"NCT05275400","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-03-08","conditions":"Type 2 Diabetes","enrollment":986},{"nctId":"NCT05362058","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-06-03","conditions":"Diabetes, Type 2 Diabetes","enrollment":928},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT06178874","phase":"NA","title":"Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-12-01","conditions":"Glycemic Control, Insulin, Critical Illness","enrollment":90},{"nctId":"NCT06132126","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-11-17","conditions":"Healthy, Type 2 Diabetes Mellitus","enrollment":66},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT04075513","phase":"PHASE4","title":"Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-09","conditions":"Type 1 Diabetes Mellitus","enrollment":343},{"nctId":"NCT04450394","phase":"PHASE2","title":"A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-01","conditions":"Type 2 Diabetes Mellitus","enrollment":278},{"nctId":"NCT04450407","phase":"PHASE2","title":"A Study of LY3209590 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-06","conditions":"Type 1 Diabetes Mellitus","enrollment":266},{"nctId":"NCT04585776","phase":"PHASE2","title":"A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-30","conditions":"Type 1 Diabetes","enrollment":31},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT03882970","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1444},{"nctId":"NCT03736785","phase":"PHASE2","title":"A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-15","conditions":"Type 2 Diabetes Mellitus","enrollment":399},{"nctId":"NCT04276428","phase":"PHASE1","title":"A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-28","conditions":"Diabetes Mellitus, Type 2","enrollment":28},{"nctId":"NCT02680457","phase":"PHASE4","title":"Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2013-11","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT03214367","phase":"PHASE3","title":"A Study of LY900014 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-17","conditions":"Type 1 Diabetes Mellitus","enrollment":1392},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT03726125","phase":"PHASE1","title":"A Study of LY3374849 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-20","conditions":"Healthy","enrollment":89},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Degludec SC","genericName":"Degludec SC","companyName":"Eli Lilly and Company","companyId":"eli-lilly","firstApprovalDate":"","aiSummary":"Degludec SC is a protein modality that acts as an insulin receptor agonist, classified as an agonist drug. It is used to treat conditions such as Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus, as well as in healthy individuals.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}